Studi Pola Penggunaan Obat Anti Tuberkulosis pada Pasien Tuberkulosis Paru

The Study of Anti Tuberculosis Drugs Used in Pulmonary Tuberculosis Patients

Keywords: Accuracy, Anti-Tuberculosis Drugs, Rational Use of Drugs, Pulmonary Tuberculosis

Abstract

Tuberculosis is one infectious disease that is still a significant problem in the health sector. This study aims to determine the pattern of anti-tuberculosis drugs in pulmonary tuberculosis patients, including the right dose, right patient, right time of administration, right route of administration, and alert for side effects based on the 2017 National Guidelines for Tuberculosis Control. The method used is descriptive with data collection systematically. Retrospectively in the form of medical record data for 2019 to 2020 at the Semarang Barat District Health Center, Semarang City, namely as many as 35 pulmonary tuberculosis patients. The study of drug side effects was traced based on the literature from several journals. The results of the univariate analysis showed that the use of anti-pulmonary tuberculosis drugs was obtained 100% at the right dose, 100% by the right patient, 100% at the time of administration, and 100% correct method of administration. Meanwhile, the side effects of using fixed-dose combination category 1 anti-tuberculosis drugs based on the literature are nausea, vomiting, redness of the urine, fever, lack of appetite, itching, and skin redness. The use of drugs in pulmonary tuberculosis patients at the Semarang Barat District Health Center, Semarang City, is in by the 2017 National Guidelines for Tuberculosis Control, a reference for the appropriate use of anti-tuberculosis drugs.

Downloads

Download data is not yet available.

References

1. World Health Organization. (2018). Global Tuberculosis Report 2018, Global Tuberculosis Report 2018. Geneva. Available at: http://apps.who.int/iris
2. World Health Organization. (2017). Global Tuberculosis Report 2017, Global Tuberculosis Report 2017. Geneva.
3. World Health Organization. (2020). Global Tuberculosis Reports, Global Tuberculosis Report 2020. Geneva. Available at: www.who.int/tb/data.
4. Departemen Kesehatan Republik Indonesia. (2005). Pharmaceutical Care Untuk Penyakit Tuberkulosis. Jakarta: Departemen Kesehatan Republik Indonesia.
5. Kementerian Kesehatan Republik Indonesia. (2017). Pengobatan Pasien Tuberkulosis, Kementerian Kesehatan Republik Indonesia. Edited by R. Handayani. Jakarta: Kementerian Kesehatan Republik Indonesia.
6. Dinas Kesehatan Provinsi Jawa Tengah. (2019). Profil Kesehatan Provinsi Jawa Tengah Tahun 2019, Dinas Kesehatan Provinsi Jawa Tengah. Semarang: Dinas Kesehatan Provinsi Jawa Tengah.
7. Kementerian Kesehatan Republik Indonesia. (2019). ‘Peraturan Menteri Kesehatan Republik Indonesia Nomor 43 Tahun 2019 Tentang Pusat Kesehatan Masyarakat’, Peraturan Menteri
Kesehatan RI No 43 tahun 2019 Tentang Pusat Kesehatan Masyarakat.
8. Kementerian Kesehatan Republik Indonesia. (2014). Buku Pedoman Nasional Pengendalian Tuberkulosis 2014. Edited by T. N. Dinihari and V. Siagian. Jakarta: Kementerian Kesehatan Republik Indonesia.
9. Ahyar, H. et al. (2020). Buku Metode Penelitian Kualitatif & Kuantitatif. I. Edited by H. Abadi. Yogyakarta: CV. Pustaka Ilmu Group.
10. Sugiyono. (2013). Statistik Untuk Penelitian. Bandung: Alfabeta.
11. Notoadmojo and Soekidjo. (2005). Metodologi Penelitian Kesehatan (Edisi Revisi). Jakarta, Rineka Cipta. Jakarta. PT. Rineka Cipta.
12. Kementerian Kesehatan Republik Indonesia. (2018). ‘Pusat Data Dan Informasi Kementerian Kesehatan Republik Indonesia’, InfoDATIN, 1(2442–7659).
13. Rahmawati, Y. (2017). Kajian Penggunaan Obat Antituberkulosis Pada Pasien Tuberkulosis Paru Dewasa Di Rumah Sakit Umum Daerah Pandan Arang Boyolali Tahun 2016, Skripsi. Universitas Muhammadiyah Surakarta.
14. Achmadi, U. F. (2009). ‘Manajemen Penyakit Berbasis Wilayah’, Kesehatan Masyarakat Nasional, 3(4), pp. 147–153.
15. Nurjana, M. A. (2015). ‘Faktor Risiko Terjadinya Tuberculosis Paru Usia Produktif (15-49 Tahun) Di Indonesia’, Media Litbangkes, 25(3), pp. 163–170.
16. Nurkumalasari, Wahyuni, D. and Ningsih, N. (2016). ‘Hubungan Karakteristik Penderita Tuberkulosis Paru Dengan Hasil Pemeriksaan Dahak Di Kabupaten Ogan Ilir’, Jurnal Keperawatan Sriwijaya, 3(2), pp. 51–58.
17. Chan-Yeung, M. et al. (2002). ‘Tuberculosis in the elderly in Hong Kong’, International Journal of Tuberculosis and Lung Disease, 6(9), pp. 771–779.
18. Badan Penelitian Dan Pengembangan Kesehatan Kementerian Kesehatan Republik Indonesia. (2013). Riset Kesehatan Dasar 2013. Jakarta.
19. Kementerian Kesehatan Republik Indonesia. (2011). Modul Penggunaan Obat Rasional, Kementerian Kesehatan RI. Jakarta: Kementerian Kesehatan Republik Indonesia.
20. Musdalipah, Karmilah, E. N. and Fakhrurazi, M. (2018). ‘Efek Samping Obat Anti Tuberkulosis (OAT) Dan Penanganannya Pada Pasien Tuberkulosis (TB) Di Puskesmas Perumnas Kota Kediri’, Jurnal Imiah Manuntung, 4(1), pp. 67–73.
Published
2022-04-30
How to Cite
Naftali, A. V., Al Farizi, G. R., & Ovikariani, O. (2022). Studi Pola Penggunaan Obat Anti Tuberkulosis pada Pasien Tuberkulosis Paru. Jurnal Surya Medika (JSM), 8(1), 161-167. https://doi.org/10.33084/jsm.v8i1.3460